Details of the Drug Reposition

General Information of This Drug (ID: DMGLAX1)

Drug Name
Halcinonide   DMGLAX1
Synonyms Halog; Halog-e
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Primary cutaneous T-cell lymphoma DIS35WVW N.A. Approved [1]
Granuloma annulare DISMOUMI N.A. Approved [1]
Exanthem DISAFOQN N.A. Approved [1]
Skin disease DISDW8R6 EA00-EM0Z Approved [2]
------------------------------------------------------------------------------------
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Seborrhoeic dermatitis DISNWVJU EA81 Discontinued in Phase 2 [3]
Contact dermatitis DISQ3AU0 EK0Z Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Atopic dermatitis DISTCP41 EA80 Discontinued in Phase 1 [5]
------------------------------------------------------------------------------------

References

1 Halcinonide FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury
4 Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
5 ClinicalTrials.gov (NCT01204450) Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma